| Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515] | Technology appraisal guidance |
| Atrasentan for treating primary IgA nephropathy [ID6588] | Technology appraisal guidance |
| Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401] | Technology appraisal guidance |
| Avapritinib for treating moderate to severe symptoms of indolent systemic mastocytosis [ID12202] | Technology appraisal guidance |
| Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570] | Technology appraisal guidance |
| Balloon cryoablation for Barrett's oesophagus | Interventional procedures guidance |
| Baloxavir marboxil for Influenza [ID6552] | Technology appraisal guidance |
| Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793] | Technology appraisal guidance |
| Baloxavir marboxil for treating influenza in babies under 1 year [ID6555] | Technology appraisal guidance |
| Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794] | Technology appraisal guidance |
| Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years
[TSID12142] | Technology appraisal guidance |
| Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108] | Technology appraisal guidance |
| Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476] | Technology appraisal guidance |
| Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [TSID12177] | Technology appraisal guidance |
| Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481] | Technology appraisal guidance |
| Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769] | Technology appraisal guidance |
| Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322] | Technology appraisal guidance |
| Bentracimab for reversing the antiplatelet activity of ticagrelor [TSID10550][ID6344] | Technology appraisal guidance |
| Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537] | Technology appraisal guidance |
| Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465] | Technology appraisal guidance |
| BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446] | Technology appraisal guidance |
| Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384] | Technology appraisal guidance |
| Bimekizumab for treating ankylosing spondylitis [TSID10334] | Technology appraisal guidance |
| Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [TSID11991] | Technology appraisal guidance |
| Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [TSID10592] | Technology appraisal guidance |